Alzheimer’s Disease Scientific Advisory Board
M. Flint Beal, M.D.
New York Presbyterian Hospital-Weill Medical College of Cornell University
Dr. M. Flint Beal is an internationally recognized authority on neurodegenerative disorders. He is the Anne Parrish Titzell Professor in the Department of Neurology and Neuroscience at the Weill Medical College of Cornell University - New York Presbyterian Hospital. Dr. Beal’s research has focused on the mechanism of neuronal degeneration in Alzheimer’s Disease, Huntington’s Disease, Parkinson’s Disease and amyotrophic lateral sclerosis (ALS). Dr. Beal is the author or co-author of more than 400 scientific articles and more than 125 books, book chapters and reviews. He serves on the editorial boards of eleven journals, including the Journal of Neurochemistry, the Journal of Neurological Sciences, Journal of Molecular Neuroscience, Experimental Neurology and Neurobiology of Disease. He is a co-editor of the “Dana Guide to Brain Health”. He serves on the scientific advisory committees of numerous foundations and is a member of the Institute of Medicine of the National Academy of Sciences. Dr. Beal received a B.A from Colgate University and his medical degree from the University of Virginia. He did his internship and first year residency in Medicine at New York-Cornell before completing his residency in Neurology at Massachusetts General Hospital.
P. Murali Doraiswamy, M.D.
Duke University Medical Center
P. Murali Doraiswamy is professor of psychiatry and geriatrics at Duke University, and a leading expert in the fields of brain aging and dementia. Dr. Doraiswamy has held many senior academic and administrative positions at Duke University’s department of psychiatry, where he was the director of psychiatry clinical trials for nearly ten years. Currently, he heads the biological psychiatry division at Duke where he leads the clinical trials unit that has conducted more than a hundred protocols evaluating novel biomarkers and therapeutics for neuropsychiatric disorders. He has also served as an advisor to leading government agencies, advocacy groups and pharma/biotech companies including GSK, Merck, Wyeth, Elan, Pfizer and others. Dr. Doraiswamy is the coauthor of more than 250 scientific publications and has chaired scientific sessions at conferences around the world. He is the coauthor of "The Alzheimer's Action Plan", an acclaimed consumer guide for people dealing with memory problems. He received his medical degree from the University of Madras and completed his residency at Duke University.
Jack de la Torre, M.D., Ph.D.
Banner Sun Health Research Institute for Alzheimer’s Disease
Dr. Jack de la Torre is a leading authority in the field of Alzheimer’s disease (AD). In 1993, he first advanced the concept of AD as a vascular disorder with neurodegenerative consequences in a series of papers that culminated in the CATCH (critically-attained threshold of cerebral hypoperfusion) hypothesis of AD. This concept has had a profound influence on research studies involving epidemiology, neuroimaging, neuropathology and therapeutics that continue to clarify the pathophysiology and pathogenesis of AD. Dr. de la Torre has edited 7 major volumes on the subject of vascular factors in AD and written a substantial number of papers on the cellular and molecular pathology associated with cerebral hypoperfusion and AD. He organized the first international conference in 1996 that dealt with the effects of vascular factors in AD titled Cerebrovascular Pathology in Alzheimer's Disease, published by the Annals of the New York Academy of Sciences. Dr. de la Torre continues his active research on Alzheimer’s disease as a Senior Scientist at the Sun Health Research Institute in Sun City, Arizona. He received a B.S. in Biology from American University, a Ph.D. in Neuroanatomy from the University of Geneva (Switzerland), and an M.D. from the University of Madrid (Spain).
© Copyright 2012 Clarimedix, Inc. - All Rights Reserved